Uncategorized
Venture capitalists look for market, path to reimbursement
SAN FRANCISCO — Clear identification of a market and a path for reimbursement are two necessary ingredients for venture capitalists in the ophthalmic space to consider before making a funding decision. But the funding is out there.“My impression is, since 2008, things have come back. There’s more money moving into the space, and it’s a relatively good time. People are chasing good science to address large unmet needs,” Emmett T. Cunningham Jr., MD, PhD, MPH, who co-moderated a panel of venture capitalists at the Glaucoma 360 New Horizons Forum, said (Read more...)